Launching Pharmaceutical Megabrands: Best Practices in Marketing Blockbusters

Research Info
Launching Pharmaceutical Megabrands: Best Practices in Marketing Blockbusters
Download FREE Excerpt
ID: SM-124
Price: $7962
Pages: 169
Questions? Call

919-403-0251

Features:
 34 Info Graphics
 31 Data Graphics
 41 Metrics
 20 Narratives
 96 Best Practices
Delivery Format:
 Shipped
Buy this research as part of a !
The findings in this Best Practices Benchmarking® Report will enable pharmaceutical executives to understand the winning strategies, practices, team structures and investment patterns that distinguish successful new product development and marketing planning. Moreover, the project findings will enable companies to move knowledgeably toward the objective of developing its own world-class marketing support capabilities.




Sales and Marketing > New Product Development and Launch


Download Free Excerpt

View TOC and List of Exhibits

Study Snapshot

Key Findings
d Industries Profiled:
Pharmaceutical; Biotech; Manufacturing; Consumer Products; Diagnostic; Health Care

Companies Profiled:
Abbott Laboratories; Sanofi-aventis; Bristol-Myers Squibb; Amgen; Boehringer-Ingelheim; Bayer; AstraZeneca; Eli Lilly and Company; Novartis; GlaxoSmithKline; Pfizer; Merck

Study Snapshot

Best Practices, LLC performed an industry-wide benchmark study on multi-phased marketing support for new products across an elite group of high performing pharmaceutical companies.



Newly updated with case studies from some of the most ground-breaking product launches, the findings in this Best Practices Benchmarking® Report will enable pharmaceutical executives to understand the winning strategies, practices, team structures and investment patterns that distinguish successful new product development and marketing planning. Moreover, the project findings will enable companies to move knowledgeably toward the objective of developing world-class marketing support capabilities.

The leading practices, managerial insights and benchmark metrics in this report are drawn from in-depth interviews (1-2 hours per interview) with executives from more than 15 leading pharmaceutical companies.

Additionally, pharmaceutical marketing support information was gathered from various other sources, including Best Practices, LLC’s proprietary databases, other public and private databases, literature reviews and on-line data research. The chart on the next page profiles the full benchmark class of companies and interviewee demographics.

Back to Top

Key Findings

The benchmark study findings are organized into an executive summary and five chapters:

  • Executive Summary
    The executive summary outlines the five top "Lessons Learned," as identified by benchmark partners and Best Practices, LLC project analysts. Studying these lessons learned will help your team members frame their overall thinking about new product development and marketing support decisions. Accompanying charts provide one-glance summaries of the key findings of the project.

Each chapter includes an overview summarizing the winning approaches of top-performing companies in the given area, benchmark data tables where relevant, and the best practices of marketing support identified by benchmark partners and Best Practices, LLC analysts.
  • Chapter 1: Developing and Deploying Integrated Marketing Support
    Replete with graphs of benchmark responses and data analysis, Chapter 1 shares the timing and frequency of key marketing activities conducted for new products by benchmark partners.
  • Chapter 2: Investing for Maximum Impact
    In Chapter 2, benchmark data of spend levels are coupled with key insights regarding resource allocation and spend differentiation among pharmaceutical companies.
  • Chapter 3: Managing Team Structure, Communication & Transition
    A key driver of development success is properly managing team structures and transitions in order to leverage product knowledge. Chapter 3 diagrams multi-phase reporting relationships and details lessons learned shared by benchmark executives. This chapter also includes practices detailing marketing career paths, team structures and transitions in order to leverage product knowledge.
  • Chapter 4: Driving Commercially Focused Drug Development
    There are many pieces of the puzzle which, when joined, prepare a product to achieve optimal commercial potential. Chapter 4 explores how thought leader input, trial strategy and pharmacoeconomic outcomes work to create a balance between clinical and commercial development.
  • Chapter 5: Preparing Market for Rapid Product Uptake
    In conjunction with preparing the drug for launch, key activities prepare the market to accept the drug. This chapter relates lessons learned for marketing strategies that employ thought leaders, public relations, advocacy and payer groups, as well as competitive intelligence.
  • Chapter 6: Blockbuster Product Case Studies
    This section highlights the marketing success stories behind 16 of the world’s top selling drugs. Learn the marketing profiles, tactics and strategies that made these products into blockbusters.
  • Appendix A: Optimizing Commercial Resources for Launch Success
    This appendix identifies best practices in optimizing commercial resource support for pharmaceutical product launches.
  • Appendix B: Marketing Metrics at a Glance Appendix B includes the leading and lagging indicators for brand performance, marketing metrics responsibilities, and timeline and competencies to evaluate marketing effectiveness.
  • Appendix C: Marketing Publications Staffing
    This appendix reveals optimal staffing levels, staff workload and staff optimization resources that are critical for marketing publications that support blockbuster product launches.


Back to Top

Related Research:

Clinical Trial Excellence Library Service 
Excellent clinical trials can significantly reduce costs by preventing delayed product launch due to trial length... (ID OPS-85)
Companies Profiled: 3M Pharmaceuticals, Sanofi-aventis, AAI Corporation, AAI Development, more ...
Price: $23100.00   Free Excerpt Available


R&D Quality Assurance Excellence Library 
A must-have for all pharmaceutical, biotech and medical device manufacturing executives, this Best Practices' R&D Quality Assurance bundle tells you everything you need to know about quality... (ID OPS-95)
Companies Profiled: aaiPharma, Sanofi-aventis, Abbott, Abbott Laboratories, more ...
Price: $21100.00   Free Excerpt Available


Market Research Excellence: Research and the Unfair Competitive Advantage 
Best Practices’ Market Research series highlights best practices in market research... (ID SMS-169)
Companies Profiled: 3M Pharmaceuticals, Sanofi-aventis, aaiPharma, Abbott Laboratories, more ...
Price: $20735.00   Free Excerpt Available


Pharma Thought Leadership: Be a Thought Leader, Manage Influential Organizations, Launch a Winner 
Best Practices’ Pharma Thought Leadership series examines thought leadership in the context of patient advocacy while creating effective relationships and global product launches... (ID SMS-156)
Companies Profiled: Abbott Laboratories, Sanofi-aventis, AstraZeneca, Bristol-Myers Squibb, more ...
Price: $18400.00


Pharmaceutical New Product Planning: Structure and Activities to Drive Growth and Profitability 
Pharmaceutical and biotech companies are increasingly under pressure to deliver effective new products in shorter time frames while minimizing development costs... (ID PSM-229)
Companies Profiled: Abbott Laboratories, Sanofi-aventis, Actelion, Alcon, more ...
Price: $9000.00   Free Excerpt Available


Success Factors and Failure Points in Oncology Product Launches 
The biopharmaceutical sector has seen dozens of new product launches in the last few years, including some notable new drugs targeting the oncology therapeutic area... (ID PSM-267)
Companies Profiled: GlaxoSmithKline, Bristol-Myers Squibb, Roche, Lilly, more ...
Price: $8500.00   Free Excerpt Available


Success Factors and Failure Points in Metabolic Product Launches 
The biopharmaceutical sector has seen dozens of new product launches in the last few years, including some notable new drugs targeting the metabolic therapeutic area... (ID PSM-266)
Companies Profiled: GlaxoSmithKline, Bristol-Myers Squibb, Roche, Lilly, more ...
Price: $8500.00   Free Excerpt Available


Success Factors and Failure Points in Cardiovascular Product Launches 
The biopharmaceutical sector has seen dozens of new product launches in the last few years, including some notable new drugs targeting the cardiovascular therapeutic area... (ID PSM-264)
Companies Profiled: GlaxoSmithKline, Bristol-Myers Squibb, Roche, Lilly, more ...
Price: $8500.00   Free Excerpt Available


Success Factors and Failure Points in Biopharmaceutical Product Launches: An Updated Road Map for Strong Market Entry 
The last several years have been marked by dozens of pharmaceutical product launches; some products took off at launch while many others fell flat... (ID PSM-261)
Companies Profiled: Abbott Laboratories, Amgen, Actelion, AstraZeneca, more ...
Price: $8500.00   Free Excerpt Available


New Product Launch Spend: What It Takes To Win In The U.S. Market 
In today’s pharmaceutical industry–where the recent product launch landscape is marked by as many failures as successes—it is critical for launch teams to understand the right level of resources required to give each new product its best chance for gaining a market foothold... (ID PSM-262)
Companies Profiled: Abbott, ProStrakan, Sanofi-aventis, Regeneron, more ...
Price: $8000.00   Free Excerpt Available


Educating KOLs, Physicians, Patients and Payers to Support Successful Product Launches 
The bio-pharmaceutical marketplace continues to evolve as new medicines and technologies create valuable market opportunities... (ID PSM-248)
Companies Profiled: GlaxoSmithKline, ARIAD, Pfizer, Integrated Communications Corp., more ...
Price: $8000.00   Free Excerpt Available


Educating the Marketplace to Support Successful Diabetes Product Launches 
The bio-pharmaceutical marketplace – including the diabetes therapeutic area – continues to evolve as new medicines and technologies create valuable market opportunities... (ID PSM-246)
Companies Profiled: GlaxoSmithKline, ARIAD, Pfizer, Integrated Communications Corp., more ...
Price: $8000.00   Free Excerpt Available


Shaping the Marketplace to Support Successful Oncology Product Launches: Tactics for Educating KOLs, Physicians, Patients and Payers 
The bio-pharmaceutical marketplace – and the oncology therapeutic area in particular – continues to evolve as new medicines and technologies create valuable market opportunities... (ID PSM-243)
Companies Profiled: GlaxoSmithKline, ARIAD, Pfizer, Integrated Communications Corp., more ...
Price: $8000.00   Free Excerpt Available


Launching Pharmaceutical Megabrands: Best Practices in Marketing Blockbusters 
The findings in this Best Practices Benchmarking® Report will enable pharmaceutical executives to understand the winning strategies, practices, team structures and investment patterns that distinguish successful new product development and marketing planning... (ID SM-124)
Companies Profiled: Abbott Laboratories, Sanofi-aventis, Bristol-Myers Squibb, Amgen, more ...
Price: $7962.00   Free Excerpt Available


Pharmaceutical New Product Commercialization: Preparing for Market Success 
Long and costly product development cycles make it essential for pharmaceutical companies to maximize limited staff and resources to the development of compounds with the greatest potential market value... (ID SM-176)
Companies Profiled: Abbott, Allergan, Alexion Pharmaceuticals, Altus Biologics, more ...
Price: $7795.00   Free Excerpt Available


Best Practices in Working with Patient Advocacy Groups: Building Effective Relationships 
Patient and professional advocacy groups play a crucial role in educating the marketplace on new medicines and treatments... (ID SM-185)
Companies Profiled: Abaxis, Abbott Laboratories, Allos Therapeutics, Amgen, more ...
Price: $7500.00   Free Excerpt Available


Best Practices for Internal Communications Regarding Brands & Disease State 
When a promising new pharmaceutical product fails to meet expectations, poor brand communications may be a contributing cause... (ID POP-229)
Companies Profiled: Abbott Laboratories, Sanofi-aventis, Actelion, Boehringer Ingelheim, more ...
Price: $7400.00   Free Excerpt Available


Raising Disease State Awareness: Best Practices in Internal Brand Messaging for New Products 
Educating the marketplace about disease state is crucial to the success of a new pharmaceutical product— especially if the product treats a medical condition that is previously unknown, socially sensitive or stigmatized or if the product is first in its class... (ID OP-106)
Companies Profiled: Abbott, Novartis, Actelion, Novo Nordisk, more ...
Price: $7200.00   Free Excerpt Available


Driving Growth Through Planning, Structure and Activities: Best Practices in Pharmaceutical New Product Planning 
New products are the lifeblood of any biopharma company and organizations are increasingly under pressure to deliver effective products in shorter time frames... (ID SM-182)
Companies Profiled: Abbott Laboratories, Sanofi-aventis, Actelion, Alcon, more ...
Price: $7000.00   Free Excerpt Available


Best Practices in Global Pharmaceutical Launches 
Discover how the world's leading pharmaceutical companies develop global launch strategies, manage launch teams, cultivate thought leader support, integrate marketing activities, and conduct a host of other critical launch activities... (ID SM-120)
Companies Profiled: Merck, Sanofi-aventis, Eli Lilly, GlaxoSmithKline, more ...
Price: $7000.00   Free Excerpt Available




All contents copyright 1998-2013 Best Practices, LLC (919) 403-0251
Site Map | Read our Privacy Policy and Copyright Information